Our Science
Our Science
Cutting-edge research and technology
Our initiatives
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change
pmi-emblem

Why Invest in PMI?

We've built the worlds most succesful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 8869

0.15 (0.17%)

Investor Relations

Latest Press Releases

Media Center
  • Press Release 17 Jan, 2020

    Philip Morris International Recognized for Business Excellence in 4th Annual One Planet Awards

  • Press Release 16 Jan, 2020

    Philip Morris International Recognized for Sustainability Action and Ambition in ‘50 Sustainability and Climate Leaders’ Project

  • News 16 Jan, 2020

    50 global sustainability leaders are working together to combat the climate crisis

  • News 20 Dec, 2019

    Behind the lens: photographing the people of PMI

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.